DMD Research: Major Pharmaceutical Company Commits to Develop Exon Skipping Drug

A multinational pharmaceutical company has committed to developing Prosensa's exon skipping compound for DMD.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.